Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Grommes

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Neuro-Oncology|April 24, 2025
Phase Ib study with expansion of ibrutinib, lenalidomide and rituximab in patients with relapsed/refractory CNS lymphomaLauren R Schaff, Anna F Piotrowski, Elena Pentsova, et al.
Neurology. Genetics|July 26, 2017
Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastomaKazimierz O Wrzeszczynski, Mayu O Frank, Takahiko Koyama, et al.
British Journal of Haematology|August 9, 2022
Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative GroupSara Steffanoni, Teresa Calimeri, Alice Laurenge, et al.
Science (New York, N.Y.)|April 6, 2013
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cellsDan Rohle, Janeta Popovici-Muller, Nicolaos Palaskas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2014
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastomaAntonio Omuro, Kathryn Beal, Philip Gutin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2024
A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS LymphomaChristian Grommes, Subhiksha Nandakumar, Lauren R Schaff, et al.
Nature|January 25, 2019
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluidAlexandra M Miller, Ronak H Shah, Elena I Pentsova, et al.
Cancer Discovery|June 17, 2017
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS LymphomaChristian Grommes, Alessandro Pastore, Nicolaos Palaskas, et al.
Acta Neuropathologica|September 12, 2025
Prospective characterization of germline variants in patients with gliomas and glioneuronal tumorsSubhiksha Nandakumar, Miika Mehine, Yelena Kemel, et al.
Cancer Discovery|May 17, 2012
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitorsIgor Vivanco, H Ian Robins, Daniel Rohle, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Neuro-Oncology|April 24, 2025
Phase Ib study with expansion of ibrutinib, lenalidomide and rituximab in patients with relapsed/refractory CNS lymphomaLauren R Schaff, Anna F Piotrowski, Elena Pentsova, et al.
Neurology. Genetics|July 26, 2017
Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastomaKazimierz O Wrzeszczynski, Mayu O Frank, Takahiko Koyama, et al.
British Journal of Haematology|August 9, 2022
Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative GroupSara Steffanoni, Teresa Calimeri, Alice Laurenge, et al.
Science (New York, N.Y.)|April 6, 2013
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cellsDan Rohle, Janeta Popovici-Muller, Nicolaos Palaskas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2014
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastomaAntonio Omuro, Kathryn Beal, Philip Gutin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2024
A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS LymphomaChristian Grommes, Subhiksha Nandakumar, Lauren R Schaff, et al.
Nature|January 25, 2019
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluidAlexandra M Miller, Ronak H Shah, Elena I Pentsova, et al.
Cancer Discovery|June 17, 2017
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS LymphomaChristian Grommes, Alessandro Pastore, Nicolaos Palaskas, et al.
Acta Neuropathologica|September 12, 2025
Prospective characterization of germline variants in patients with gliomas and glioneuronal tumorsSubhiksha Nandakumar, Miika Mehine, Yelena Kemel, et al.
Cancer Discovery|May 17, 2012
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitorsIgor Vivanco, H Ian Robins, Daniel Rohle, et al.
Pageof 10